| |
| |
|
| Insider
Information: |
Alles Mark J |
| Relationship: |
Director |
| City: |
Summit |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
18,761 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$1,356,090 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
18,761 |
|
|
| Total
Value |
$1,356,090 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
2
|
0
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
1
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
 -13.3%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Celgene Corp |
CELG |
|
2019-11-20 |
0 |
2019-11-20 |
0 |
Premium* |
|
|
Syros Pharmaceuticals, Inc. |
SYRS |
Director |
2023-09-16 |
3,666 |
2020-05-13 |
0 |
Premium* |
|
|
Turning Point Therapeutics, Inc. |
TPTX |
Director |
2022-08-17 |
0 |
2021-06-21 |
0 |
Premium* |
|
|
Biomarin Pharmaceutical Inc |
BMRN |
Director |
2023-05-23 |
15,095 |
2022-01-03 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
62 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CELG |
Celgene Corp |
CEO, CHAIRMAN OF BOARD |
• • – |
2019-11-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(6,252) |
0 |
0 |
- |
|
| CELG |
Celgene Corp |
CEO, CHAIRMAN OF BOARD |
• • – |
2019-11-20 |
4 |
D |
$0.00 |
$0 |
D/D |
(366,495) |
0 |
0 |
- |
|
| CELG |
Celgene Corp |
CEO, CHAIRMAN OF BOARD |
• • – |
2019-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
145,229 |
366,495 |
0 |
- |
|
| SYRS |
Syros Pharmaceuticals, In... |
Director |
– • – |
2020-05-13 |
4 |
B |
$8.86 |
$88,590 |
D/D |
10,000 |
10,000 |
2.39 |
% |
|
| TPTX |
Turning Point Therapeutic... |
Director |
– • – |
2021-06-21 |
4 |
B |
$81.34 |
$162,680 |
D/D |
2,000 |
2,000 |
2.39 |
% |
|
| BMRN |
Biomarin Pharmaceutical I... |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,300 |
2,300 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Director |
– • – |
2022-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,980 |
7,280 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
Director |
– • – |
2022-08-17 |
4 |
D |
$76.00 |
$152,000 |
D/D |
(2,000) |
0 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Director |
– • – |
2022-10-31 |
4 |
B |
$86.75 |
$314,469 |
D/D |
3,625 |
10,905 |
2.39 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Director |
– • – |
2023-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
4,190 |
15,095 |
0 |
- |
|
| SYRS |
Syros Pharmaceuticals, In... |
Director |
– • – |
2023-09-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,666 |
3,666 |
0 |
- |
|
| CELG |
Celgene Corp |
Chief Commercial OfficerOffice |
• – – |
2012-02-15 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,409 |
|
- |
|
62 Records found
|
|
Page 3 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
